Your browser is no longer supported. Please, upgrade your browser.
Settings
OBSV ObsEva SA daily Stock Chart
OBSV [NASD]
ObsEva SA
Index- P/E- EPS (ttm)-2.11 Insider Own15.51% Shs Outstand46.40M Perf Week-21.83%
Market Cap506.69M Forward P/E- EPS next Y-2.03 Insider Trans0.00% Shs Float36.16M Perf Month-34.30%
Income-72.10M PEG- EPS next Q-0.46 Inst Own66.70% Short Float0.25% Perf Quarter-14.62%
Sales0.02M P/S33779.20 EPS this Y-120.30% Inst Trans22.02% Short Ratio0.67 Perf Half Y-22.72%
Book/sh4.70 P/B2.32 EPS next Y-2.00% ROA-53.40% Target Price31.00 Perf Year41.09%
Cash/sh3.59 P/C3.04 EPS next 5Y- ROE-59.30% 52W Range6.15 - 20.35 Perf YTD11.89%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-46.34% Beta-
Dividend %- Quick Ratio14.20 Sales past 5Y- Gross Margin- 52W Low77.56% ATR1.02
Employees39 Current Ratio14.20 Sales Q/Q-16.70% Oper. Margin- RSI (14)26.09 Volatility9.11% 7.14%
OptionableNo Debt/Eq0.00 EPS Q/Q23.00% Profit Margin- Rel Volume0.71 Prev Close11.97
ShortableYes LT Debt/Eq0.00 EarningsAug 08 BMO Payout- Avg Volume132.77K Price10.92
Recom1.60 SMA20-22.95% SMA50-26.06% SMA200-13.28% Volume93,660 Change-8.77%
Aug-15-18Resumed Leerink Partners Outperform $25
Aug-07-18Initiated Wedbush Outperform $34
Jul-19-18Initiated Credit Suisse Outperform $24
Oct-11-17Reiterated H.C. Wainwright Buy $27 → $25
Sep-15-17Initiated RBC Capital Mkts Outperform $22
Aug-16-17Resumed Leerink Partners Outperform $18
Jun-29-17Initiated H.C. Wainwright Buy $27
Feb-21-17Initiated Leerink Partners Outperform $21
Feb-21-17Initiated Jefferies Buy $21
Feb-21-17Initiated Credit Suisse Outperform $27
Aug-10-18 01:31AM  ObsEva SA to Participate in Wedbush PacGrow Healthcare Conference August 14-15, 2018 GlobeNewswire
Aug-08-18 07:30AM  ObsEva SA (OBSV) Reports Q2 Loss, Misses Revenue Estimates Zacks
06:00AM  ObsEva SA to Host Earnings Call ACCESSWIRE
01:01AM  ObsEva Reports Second Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
Aug-02-18 05:53AM  ObsEva SA (OBSV) Sees Hammer Chart Pattern: Time to Buy? Zacks +8.73%
Jul-31-18 09:36AM  ObsEva SA to Hold Second Quarter 2018 Financial Results and Business Update Call on August 8, 2018 GlobeNewswire
01:31AM  ObsEva SA to Hold Second Quarter 2018 Financial Results and Business Update Call on August 8, 2018 GlobeNewswire
Jul-25-18 01:32AM  ObsEva Expands Executive Team Hiring a Chief Commercial Officer GlobeNewswire
Jul-13-18 01:31AM  ObsEva SA to start trading today on the SIX Swiss Exchange GlobeNewswire +9.16%
Jul-06-18 02:31AM  ObsEva plans Swiss listing; trading debut on July 13 Reuters
01:31AM  ObsEva SA Shares to Begin Trading on SIX Swiss Exchange GlobeNewswire
Jun-20-18 02:50AM  ObsEva Announces Pricing of Follow-on Public Offering GlobeNewswire -7.08%
02:50AM  ObsEva Announces Pricing of Follow-on Public Offering GlobeNewswire
Jun-18-18 04:33PM  ObsEva Announces Launch of Proposed Follow-on Public Offering GlobeNewswire +22.82%
04:32PM  ObsEva Announces Launch of Proposed Follow-on Public Offering GlobeNewswire
07:01AM  ObsEva SA Achieves Primary and Secondary Endpoints for EDELWEISS Phase 2b Clinical Trial of Linzagolix (OBE2109) in Women with Endometriosis GlobeNewswire
07:00AM  ObsEva SA Achieves Primary and Secondary Endpoints for EDELWEISS Phase 2b Clinical Trial of Linzagolix (OBE2109) in Women with Endometriosis GlobeNewswire
Jun-15-18 04:01PM  ObsEva SA to Hold Investor Call to Announce Topline Results of the EDELWEISS Phase 2b Clinical Trial of Linzagolix (OBE2109) in Women with Endometriosis-Associated Pain on Monday June 18, 2018 GlobeNewswire
Jun-01-18 07:01AM  ObsEva SA to Seek SIX Share Listing GlobeNewswire
May-31-18 07:02AM  ObsEva SA to Participate in Jefferies Global Healthcare Conference June 5-8, 2018 GlobeNewswire
07:01AM  ObsEva SA to Participate in Jefferies Global Healthcare Conference June 5-8, 2018 GlobeNewswire
May-18-18 11:52AM  Edited Transcript of OBSV.O earnings conference call or presentation 16-May-18 12:00pm GMT Thomson Reuters StreetEvents
May-17-18 07:16PM  ObsEva SA Ordinary Shares (OBSV) Q1 2018 Earnings Conference Call Transcript Motley Fool +5.68%
May-16-18 07:15AM  With A -121.60% Earnings Drop, Did ObsEva SA (NASDAQ:OBSV) Really Underperform? Simply Wall St.
07:01AM  ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
07:01AM  ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
May-14-18 07:35AM  Consolidated Research: 2018 Summary Expectations for Care, Unilever, CECO Environmental, Carter's, ObsEva SA, and ViewRay Fundamental Analysis, Key Performance Indications GlobeNewswire
May-08-18 07:01AM  ObsEva SA to Hold First Quarter 2018 Financial Results and Business Update Call on May 16, 2018 GlobeNewswire +10.16%
Apr-23-18 07:01AM  ObsEva Announces Upcoming Presentations Related to its Endometriosis and Uterine Fibroid Development Programs with its Novel Oral GnRH Receptor Antagonist OBE2109 (KLH-2109) GlobeNewswire -5.83%
07:01AM  ObsEva Announces Upcoming Presentations Related to its Endometriosis and Uterine Fibroid Development Programs with its Novel Oral GnRH Receptor Antagonist OBE2109 (KLH-2109) GlobeNewswire
Apr-16-18 07:01AM  ObsEva SA to Host Key Opinion Leader Meeting on In Vitro Fertilization (IVF) April 26, 2018 in New York City GlobeNewswire
Mar-28-18 07:55AM  Analysis: Positioning to Benefit within Fortress Transportation and Infrastructure Investors, Turquoise Hill Resources, FactSet Research, Shaw Communications, El Pollo Loco, and ObsEva SA Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Mar-26-18 03:26PM  ObsEva SA to Participate in the H.C. Wainwright Annual Global Life Sciences Conference April 8-10, 2018 GlobeNewswire
07:01AM  ObsEva SA to Participate in the H.C. Wainwright Annual Global Life Sciences Conference April 8-10, 2018 GlobeNewswire
Mar-12-18 11:11AM  Edited Transcript of OBSV.O earnings conference call or presentation 9-Mar-18 1:00pm GMT Thomson Reuters StreetEvents
Mar-09-18 08:48AM  ObsEva Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Business Update GlobeNewswire
07:01AM  ObsEva Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Business Update GlobeNewswire
Mar-02-18 07:01AM  ObsEva SA to Hold Fourth Quarter and Year-end 2017 Financial Results and Business Update Call on March 9, 2018 GlobeNewswire +6.80%
07:01AM  ObsEva SA to Hold Fourth Quarter and Year-end 2017 Financial Results and Business Update Call on March 9, 2018 GlobeNewswire
Mar-01-18 07:01AM  ObsEva Announces Presentations Related to its Pre-term labor (PTL) Development Program at SRI 2018 Annual Meeting GlobeNewswire -5.84%
07:01AM  ObsEva Announces Presentations Related to its Pre-term labor (PTL) Development Program at SRI 2018 Annual Meeting GlobeNewswire
Feb-28-18 07:00AM  Wired News ObsEva Released Positive Top-line Results from IMPLANT2 Phase-3 Clinical Trial Evaluating Nolasiban in IVF ACCESSWIRE
Feb-26-18 02:18PM  ARCA biopharma And ObsEva Just Put Out Clinical Trial Data Market Exclusive
07:01AM  ObsEva SA Reports Positive Topline Results from IMPLANT2 Phase 3 Clinical Trial of Nolasiban in IVF GlobeNewswire
07:01AM  ObsEva SA Reports Positive Topline Results from IMPLANT2 Phase 3 Clinical Trial of Nolasiban in IVF GlobeNewswire
Feb-23-18 04:01PM  ObsEva SA to Hold Investor Call to announce Topline Results of the IMPLANT2 phase 3 Clinical Trial of Nolasiban in IVF/ICSI on Monday February 26, 2018 GlobeNewswire +6.43%
Feb-07-18 07:01AM  ObsEva SA to present at the LEERINK Partners 7th Annual Global Healthcare Conference February 14th 2018 GlobeNewswire
07:01AM  ObsEva SA to present at the LEERINK Partners 7th Annual Global Healthcare Conference February 14th 2018 GlobeNewswire
Feb-01-18 07:01AM  Dr. Ernest Loumaye, CEO of ObsEva SA returns to work following a personal leave for medical reasons GlobeNewswire -5.12%
Jan-05-18 07:01AM  ObsEva SA to Participate in JP Morgan Healthcare Conference January 8 - 11, 2018 GlobeNewswire
Dec-07-17 07:02AM  ObsEva SA to Participate in BMO Healthcare Conference December 14th 2017 GlobeNewswire
Dec-05-17 07:01AM  ObsEva Initiates PROLONG, the Phase 2a Clinical Trial of OBE022 in Preterm Labor GlobeNewswire
Nov-21-17 02:31AM  Edited Transcript of OBSV.O earnings conference call or presentation 14-Nov-17 1:00pm GMT Thomson Reuters StreetEvents -6.70%
Nov-14-17 07:01AM  ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update GlobeNewswire
07:01AM  ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update GlobeNewswire
Nov-07-17 07:02AM  ObsEva SA Announces the Completion of Patient Recruitment in the EDELWEISS Phase 2b Clinical Trial of OBE2109 for the Treatment of Endometriosis GlobeNewswire
Oct-31-17 07:01AM  ObsEva SA to Hold Third Quarter 2017 Financial Results and Business Update Call on November 14, 2017 and Present at Credit Suisse and Jefferies Investor Conferences in November GlobeNewswire
07:01AM  ObsEva SA to Hold Third Quarter 2017 Financial Results and Business Update Call on November 14, 2017 and Present at Credit Suisse and Jefferies Investor Conferences in November GlobeNewswire
Oct-10-17 08:01AM  ObsEva SA Announces $60.0 Million Private Placement with Existing and New Investors GlobeNewswire +11.36%
Sep-11-17 07:02AM  ObsEva SA Announces Presentation Related to its PGF2alpha Receptor Antagonist at ACCP 2017 Annual Meeting GlobeNewswire
07:02AM  ObsEva SA Announces Presentation Related to its PGF2alpha Receptor Antagonist at ACCP 2017 Annual Meeting GlobeNewswire
Sep-06-17 07:01AM  ObsEva SA Announces the Completion of Patient Recruitment in the IMPLANT2 Phase 3 Clinical Trial in Assisted Reproductive Technology Ahead of Schedule GlobeNewswire
Aug-30-17 07:01AM  ObsEva SA to Attend Baird Global Healthcare Conference and Rodman & Renshaw Annual Global Investment Conference in NYC GlobeNewswire
Aug-28-17 07:40AM  Featured Company News - IMRALDI(R), Biogen's Version of AbbVie's Humira(R), Approved in the European Union ACCESSWIRE +5.64%
Aug-18-17 06:11PM  Edited Transcript of OBSV.O earnings conference call or presentation 15-Aug-17 9:00pm GMT Thomson Reuters StreetEvents
Aug-15-17 04:07PM  ObsEva Reports Second Quarter 2017 Financial Results and Provides Business Update GlobeNewswire
Aug-07-17 07:01AM  ObsEva SA to Hold Second Quarter 2017 Financial Results/Business Update Call on August 15, 2017 and Present at Wedbush PacGrow Healthcare Conference in NYC on August 16, 2017 GlobeNewswire
07:01AM  ObsEva SA to Hold Second Quarter 2017 Financial Results/Business Update Call on August 15, 2017 and Present at Wedbush PacGrow Healthcare Conference in NYC on August 16, 2017 GlobeNewswire
Jun-29-17 01:38PM  An 'Unsung Potential Winner,' ObsEva Initiated At Buy Benzinga +27.12%
07:02AM  ObsEva Announces Presentations Related to its Assisted Reproductive Technology (ART) and Pre-term labor (PTL) Development Programs at ESHRE 2017 Annual Meeting GlobeNewswire
Jun-15-17 08:40AM  What Falling Estimates & Price Mean for ObsEva (OBSV) Zacks
Jun-07-17 07:02AM  ObsEva SA Announces the Completion of a Phase 1 PK/PD Clinical Trial Evaluating Different Doses of OBE2109 and Add-Back Therapy GlobeNewswire
May-31-17 07:02AM  ObsEva SA to Attend Jefferies Healthcare Conference in NYC GlobeNewswire
07:01AM  ObsEva SA to Attend Jefferies Healthcare Conference in NYC GlobeNewswire
May-18-17 07:01AM  ObsEva Reports First Quarter 2017 Financial Results and Business Update GlobeNewswire -6.93%
07:01AM  ObsEva Reports First Quarter 2017 Financial Results and Business Update GlobeNewswire
06:31AM  ObsEva Announces the Completion of a Phase 1 Drug-Drug Interaction Study with OBE022 GlobeNewswire
06:31AM  ObsEva Announces the Completion of a Phase 1 Drug-Drug Interaction Study with OBE022 GlobeNewswire
May-16-17 07:01AM  ObsEva SA to Attend BioEquity Europe 2017 in Paris GlobeNewswire
07:01AM  ObsEva SA to Attend BioEquity Europe 2017 in Paris GlobeNewswire
May-11-17 07:02AM  ObsEva SA to Hold First Quarter 2017 Financial Results and Business Update Call on Thursday, May 18, 2017 GlobeNewswire
07:01AM  ObsEva SA to Hold First Quarter 2017 Financial Results and Business Update Call on Thursday, May 18, 2017 GlobeNewswire
Apr-25-17 07:01AM  ObsEva SA Initiates Phase 3 Clinical Program for OBE2109 in Uterine Fibroids GlobeNewswire
07:01AM  ObsEva SA Initiates Phase 3 Clinical Program for OBE2109 in Uterine Fibroids GlobeNewswire
Mar-24-17 12:02PM  ObsEva SA to Attend Needham Annual Healthcare Conference in NYC GlobeNewswire
12:01PM  ObsEva SA to Attend Needham Annual Healthcare Conference in NYC GlobeNewswire
Mar-17-17 07:02AM  ObsEva to Present Pharmacology Results Demonstrating OBE022 Exerts a Synergistic Effect in Combination with Standard of Care in Animal Model for Preterm Labor GlobeNewswire
07:01AM  ObsEva to Present Pharmacology Results Demonstrating OBE022 Exerts a Synergistic Effect in Combination with Standard of Care in Animal Model for Preterm Labor GlobeNewswire
Mar-07-17 07:02AM  ObsEva Starts Phase 3 Clinical Program for Nolasiban in ART GlobeNewswire -5.16%
07:01AM  ObsEva Starts Phase 3 Clinical Program for Nolasiban in ART GlobeNewswire
Feb-21-17 06:55AM  Coverage initiated on ObsEva by Leerink Partners, Jefferies and Credit Suisse
Feb-14-17 09:20AM  Biotech IPOs Slow As Trump-Sown Uncertainty Rattles Nerves On Wall Street Forbes
Feb-06-17 12:31PM  Robust Start for Pharmaceutical IPOs In 2017 Investopedia
12:31PM  Robust Start for Pharmaceutical IPOs In 2017 at Investopedia
Feb-03-17 07:01AM  ObsEva SA to Attend LEERINK Partners Global Healthcare Conference in NYC GlobeNewswire +5.70%
07:01AM  ObsEva SA to Attend LEERINK Partners Global Healthcare Conference in NYC GlobeNewswire
Jan-27-17 06:15AM  Cambridges Jounce raises hopes as first Mass. biotech of 2017 to go public at bizjournals.com
06:15AM  Cambridges Jounce raises hopes as first Mass. biotech of 2017 to go public American City Business Journals
Jan-26-17 01:30PM  Nasdaq Welcomes ObsEva SA (Nasdaq: OBSV) to The Nasdaq Stock Market GlobeNewswire
06:00AM  ObsEva SA (Nasdaq: OBSV) to Ring The Nasdaq Stock Market Opening Bell in Celebration of its IPO GlobeNewswire
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age. The company was founded in 2012 and is headquartered in Plan-les-Ouates, Switzerland.